With the turning of the midpoint of 2023, the arena of drug pricing sees an influx of developments. The Centers for Medicare & Medicaid Services (CMS) finalized its guidance to prepare for unprecedented price negotiations, putting a highlight on the initial 10 drugs covered under the Innovation and Regulatory Affairs (IRA). Meanwhile, the constitutionality of the IRA’s drug-pricing provisions has begun to be contested extensively, providing another layer of complexity to the issue at hand.
On the legislative front, Congress has been proactive, mulling over several novel pieces of legislation. Specifically, these bills aim to curtail certain Pharmacy Benefit Manager (PBM) practices and scrutinize particular types of conduct by drug manufacturers.
Reacting to the CMS’ decision, the drug pricing industry has seen considerable shifts. The detailed guidance provides a groundwork for negotiating pricing on selected drugs. Specifically, these are the drugs covered under the IRA – a substantial move that marks a shift in the calculus for drug manufacturers and insurers alike.
Another point demanding attention within the industry is the increasing number of constitutional challenges against the IRA’s drug pricing provisions. As various stakeholders question the legitimacy, the debates originating from these challenges are expected to significantly influence the future of drug pricing.
Simultaneously, legislative mechanisms are being examined by Congress. A series of prospective new bills are under consideration, pointing to an expanded regulatory scope of PBM practices. By primarily focusing on the more contentious PBM practices, these bills have started igniting debates among key stakeholders in the industry. Corporations, in particular, are carefully considering the potential impacts of these changes.
Also noteworthy is the congressional spotlight on the conduct of drug manufacturers, with various bills aiming to restrict conduct deemed counterproductive or harmful. A thorough understanding of the current challenges and potential legislative changes in the drug pricing landscape is critical for corporations and law firms alike, who must navigate this complex environment with due diligence and strategic foresight.
Professionals interested in further details can read the complete coverage on JD Supra, and stay informed with every nuance in these evolving legal landscapes.